Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…